TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #14906 · Jul 3

#typescript#ai#anthropic#artifacts#assistant_api#aws#azure#chatgpt#chatgpt_clone#claude#clone#dall_e_3#deepseek#gemini#google#librechat#o1#openai#plugins#vision#webui LibreChat is a free, open-source AI chatbot platform that lets you use many AI models like OpenAI, Anthropic, and AWS in one place. It offers advanced features such as secure code execution in multiple programming languages, AI assistants that can handle files and tools without coding, and the ability to generate images and diagrams directly in chat. You can search conversations easily, manage multiple chat threads, and customize the interface to fit your needs. LibreChat supports multiple languages, speech input/output, and secure multi-user access. It can be deployed locally or on the cloud, giving you flexibility and control over your AI experience. This means you get a powerful, customizable AI assistant without needing to pay for ChatGPT Plus or rely on a single provider[1][3][5]. https://github.com/danny-avila/LibreChat

Results

2 similar posts found

Search: #molnupiravir

当前筛选 #molnupiravir清除筛选
ÉTIENNE CHOUARD

@chouard · Post #229 · 10/26/2021, 08:48 PM

Donc quand 2 grands fabricants de médicaments génériques en #Inde stoppent leur essai du #Molnupiravir de #Merck, parce qu'il ne marche pas sur les #Covid19 modérés... Olivier #Véran en commande 50.000 doses. 😅 D'ailleurs Merck a arrêté lui-même son essai sur les patients #Covid hospitalisés (pour tester en outpatients)... La boussole sud quoi https://www.reuters.com/business/healthcare-pharmaceuticals/aurobindo-pharma-stop-molnupiravir-trial-moderate-covid-19-patients-2021-10-08/https://www.businesswire.com/news/home/20210415005258/en/https://www.lavoixdunord.fr/1090028/article/2021-10-26/c-est-quoi-le-molnupiravir-medicament-anti-covid-dont-la-france-commande-50-000

香港抗疫資訊頻道

@HKFIGHTCOVID19 · Post #4759 · 03/15/2022, 11:22 PM

【新冠口服藥處方應用💊】政府已根據專家意見,通過醫管局採購合適數量的新冠口服抗病毒藥物,其中默沙東藥廠的莫納皮拉韋(Molnupiravir)已全數抵港並正在應用,另一款輝瑞藥廠的帕克斯洛維德(Paxlovid)首批昨日(3月14日)亦已抵港,其他批次未來兩三個月會陸續到港👏🏻👏🏻。 醫生會按臨牀指引📃和病人情況處方藥物給以下合適病人😷: 📍公立醫院住院病人 📍指定診所社區確診者 📍安老院舍確診患者 📍私家醫院新冠病人 臨床研究結果顯示,新冠口服藥有機會減低有高危因素患者的住院及死亡風險🙏🏻。我們會繼續購買及儲備相關藥物💪🏻💪🏻。 新聞公報:https://bit.ly/3tbeim6 #同心抗疫#2019冠狀病毒病#新冠口服抗病毒藥物#默沙東#莫納皮拉韋#Molnupiravir#輝瑞#帕克斯洛維德#Paxlovid#臨牀指引#新冠病人#減住院及死亡風險#全民同心抗疫